Shots:
Garret spoke about the approval of the first NGS-based companion diagnostic to aid in selecting NSCLC patients with HER2 activating mutations for treatment with ENHERTU
Garret also talked about the Oncomine Dx Target Test and its availability for different targeted therapies in multiple geographies
The interview highlights how Thermo Fisher is working to develop accessible CDx solutions…
